|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: IDO2 |
Gene summary for IDO2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | IDO2 | Gene ID | 169355 |
| Gene name | indoleamine 2,3-dioxygenase 2 | |
| Gene Alias | INDOL1 | |
| Cytomap | 8p11.21 | |
| Gene Type | protein-coding | GO ID | GO:0002376 | UniProtAcc | Q6ZQW0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 169355 | IDO2 | RNA-P17T-P17T-2 | Human | Lung | IAC | 1.99e-06 | 7.51e-01 | 0.3371 |
| 169355 | IDO2 | RNA-P17T-P17T-4 | Human | Lung | IAC | 4.71e-02 | 4.79e-01 | 0.343 |
| 169355 | IDO2 | RNA-P17T-P17T-6 | Human | Lung | IAC | 2.66e-08 | 8.53e-01 | 0.3385 |
| 169355 | IDO2 | RNA-P17T-P17T-8 | Human | Lung | IAC | 5.26e-09 | 8.00e-01 | 0.3329 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| IDO2 | SNV | Missense_Mutation | c.127C>A | p.Pro43Thr | p.P43T | Q6ZQW0 | protein_coding | deleterious(0.02) | possibly_damaging(0.787) | TCGA-A8-A06R-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | CR | |
| IDO2 | SNV | Missense_Mutation | c.944N>A | p.Pro315His | p.P315H | Q6ZQW0 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-A8-A09W-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| IDO2 | SNV | Missense_Mutation | novel | c.917N>C | p.Leu306Pro | p.L306P | Q6ZQW0 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-UL-AAZ6-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | herceptin | SD |
| IDO2 | insertion | Nonsense_Mutation | novel | c.1252_1253insGTTTTTTTTTTTTTAACCAATTGATAAAACCAAATATAAATTAAAATGT | p.Pro418ArgfsTer15 | p.P418Rfs*15 | Q6ZQW0 | protein_coding | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| IDO2 | SNV | Missense_Mutation | c.97N>G | p.His33Asp | p.H33D | Q6ZQW0 | protein_coding | tolerated(0.07) | benign(0.046) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| IDO2 | SNV | Missense_Mutation | novel | c.453G>C | p.Trp151Cys | p.W151C | Q6ZQW0 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-VS-A8EK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
| IDO2 | SNV | Missense_Mutation | rs765222349 | c.889N>T | p.Arg297Cys | p.R297C | Q6ZQW0 | protein_coding | tolerated(0.29) | benign(0.003) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| IDO2 | SNV | Missense_Mutation | c.370N>A | p.Leu124Ile | p.L124I | Q6ZQW0 | protein_coding | tolerated(0.45) | probably_damaging(0.933) | TCGA-CA-6718-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
| IDO2 | SNV | Missense_Mutation | c.1199T>G | p.Val400Gly | p.V400G | Q6ZQW0 | protein_coding | deleterious(0) | benign(0.326) | TCGA-CM-5862-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| IDO2 | SNV | Missense_Mutation | rs752076671 | c.514N>T | p.Pro172Ser | p.P172S | Q6ZQW0 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D5-6929-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | oxaliplatinum+ | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 169355 | IDO2 | ENZYME | 2,3-diamino-benzo[b]thiophene derivative 5 | |||
| 169355 | IDO2 | ENZYME | 2,3-diamino-benzo[b]thiophene derivative 4 | |||
| 169355 | IDO2 | ENZYME | inhibitor | 381118836 | ||
| 169355 | IDO2 | ENZYME | 2,3-diamino-benzo[b]thiophene derivative 8 | |||
| 169355 | IDO2 | ENZYME | 2,3-diamino-benzo[b]thiophene derivative 2 | |||
| 169355 | IDO2 | ENZYME | 2,3-diamino-benzo[b]thiophene derivative 6 | |||
| 169355 | IDO2 | ENZYME | 2,3-diamino-benzo[b]thiophene derivative 7 | |||
| 169355 | IDO2 | ENZYME | 2,3-diamino-benzo[b]thiophene derivative 1 | |||
| 169355 | IDO2 | ENZYME | PMID27172114-Compound-30 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |